Last reviewed · How we verify
NCT05909774: M1-M2
Assessment of the Interest of the Atalante Device for Patients With Manual Wheelchairs
NA trial testing Test with Atalante exoskeleton in "continuous walk" type in Complete Motor Paraplegia in 10 participants. Completed in 8 September 2017.
8 September 2017
Quick facts
| Lead sponsor | Wandercraft |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | device feasibility |
| Enrollment | 10 |
| Start date | 9 December 2016 |
| Primary completion | 8 September 2017 |
| Estimated completion | 8 September 2017 |
| Sites | 1 location across France |
Drugs / interventions tested
- Test with Atalante exoskeleton in "continuous walk" type
Conditions studied
- Complete Motor Paraplegia — all drugs for Complete Motor Paraplegia →
Sponsor
Wandercraft
Who can join
Adults 18 to 60, any sex, with Complete Motor Paraplegia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The loss of standing and walking capabilities in a paraplegic person is most often the result of damage to the spinal cord, either traumatic (accidental) or pathological and has both a somatic and a psychological impact on the quality of life, the risk of depression, and the difficulty of socio-professional reintegration in a society that is not adapted to people with disabilities. A motorized mechanical exoskeleton is an external device intended to compensate for a muscular or neurological deficiency enabling paraplegics to stand and walk again. The Atalante exoskeleton, designed by Wandercraft company allows patients to stand upright and walk without the aid of crutches. This early study was the first clinical investigation of the Atalante exoskeleton performed early in the development. It was used to evaluate the device design concept with respect to initial clinical safety and device functionality and guided further device modifications.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05909774
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Wandercraft trials
Trials by the same sponsor.
- NCT07536386 — Self-balancing Personal Exoskeleton for SCI (WIP) · NA · recruiting
- NCT07222033 — Self-balancing Personal Exoskeleton for SCI (WINY) · NA · recruiting
- NCT06814015 — Self-balancing Personal Exoskeleton for SCI (Site 2) · NA · recruiting
- NCT06777576 — Self-balancing Personal Exoskeleton for SCI · NA · recruiting
- NCT06715631 — Human Factors Validation Testing of the Wandercraft Personal Exoskeleton · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05909774 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wandercraft
- Last refreshed: 18 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05909774.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing